4.7 Review

The Role of AGE-RAGE Signalling as a Modulator of Gut Permeability in Diabetes

期刊

出版社

MDPI
DOI: 10.3390/ijms23031766

关键词

advanced glycation endproducts; receptor for advanced glycation endproducts; diabetes; intestinal permeability

向作者/读者索取更多资源

There is increasing evidence for the role of intestinal permeability in the pathogenesis of diabetes, and the binding of advanced glycation endproducts to RAGE receptor may trigger proinflammatory signaling cascade, leading to intestinal inflammation and increased permeability, thus contributing to the development of diabetes complications.
There is increasing evidence for the role of intestinal permeability as a contributing factor in the pathogenesis of diabetes; however, the molecular mechanisms are poorly understood. Advanced glycation endproducts, of both exogenous and endogenous origin, have been shown to play a role in diabetes pathophysiology, in part by their ligation to the receptor for advanced glycation endproducts (RAGE), leading to a proinflammatory signalling cascade. RAGE signalling has been demonstrated to play a role in the development of intestinal inflammation and permeability in Crohn's disease and ulcerative colitis. In this review, we explore the role of AGE-RAGE signalling and intestinal permeability and explore whether activation of RAGE on the intestinal epithelium may be a downstream event contributing to the pathogenesis of diabetes complications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Transplantation

Targeted deletion of nicotinamide adenine dinucleotide phosphate oxidase 4 from proximal tubules is dispensable for diabetic kidney disease development

Vicki Thallas-Bonke, Sih Min Tan, Runa S. Lindblom, Matthew Snelson, Cesare Granata, Jay Chandra Jha, Karly C. Sourris, Adrienne Laskowski, Anna Watson, Michel Tauc, Isabelle Rubera, Guoping Zheng, Ajay M. Shah, David C. H. Harris, Mahmoud H. Elbatreek, Phillip Kantharidis, Mark E. Cooper, Karin Jandeleit-Dahm, Melinda T. Coughlan

Summary: Genetic deletion of Nox4 from the proximal tubules does not influence the development of DKD, indicating that the localization of Nox4 within this kidney compartment is dispensable for the pathogenesis of chronic kidney disease in the setting of diabetes.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

Article Endocrinology & Metabolism

Gut microbiome, prebiotics, intestinal permeability and diabetes complications

Matthew Snelson, Cassandra de Pasquale, Elif I. Ekinci, Melinda T. Coughlan

Summary: Changes in gut microbiota in diabetes can lead to decreased intestinal barrier function, affecting systemic inflammation and worsening microvascular diabetes complications. Prebiotics offer a dietary approach to increase beneficial short chain fatty acids produced by gut microbiota and improve intestinal permeability in diabetes.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Article Food Science & Technology

Long Term High Protein Diet Feeding Alters the Microbiome and Increases Intestinal Permeability, Systemic Inflammation and Kidney Injury in Mice

Matthew Snelson, Rachel Elise Clarke, Tuong-Vi Nguyen, Sally Anne Penfold, Josephine Maree Forbes, Sih Min Tan, Melinda Therese Coughlan

Summary: The study found that long-term consumption of a high protein diet in mice can lead to kidney injury, systemic inflammation, increased gastrointestinal permeability, and alterations in the gut microbiome structure.

MOLECULAR NUTRITION & FOOD RESEARCH (2021)

Article Nutrition & Dietetics

Targeting Methylglyoxal in Diabetic Kidney Disease Using the Mitochondria-Targeted Compound MitoGamide

Sih Min Tan, Runa S. J. Lindblom, Mark Ziemann, Adrienne Laskowski, Cesare Granata, Matthew Snelson, Vicki Thallas-Bonke, Assam El-Osta, Carlos D. Baeza-Garza, Stuart T. Caldwell, Richard C. Hartley, Thomas Krieg, Mark E. Cooper, Michael P. Murphy, Melinda T. Coughlan

Summary: The study investigated the use of MitoGamide to target methylglyoxal within the mitochondria for treating diabetic kidney disease (DKD), but found that it did not substantially improve the renal phenotype in an experimental model of diabetes. The findings suggest that targeting methylglyoxal within the mitochondria using MitoGamide may not be a valid therapeutic approach for DKD, and that other mitochondrial targets or processes upstream should be the focus of therapy.

NUTRIENTS (2021)

Review Endocrinology & Metabolism

Novel Therapies for Kidney Disease in People With Diabetes

Nayana Khurana, Steven James, Melinda T. Coughlan, Richard J. MacIsaac, Elif Ekinci

Summary: DKD is a growing burden, leading to the discovery of new therapies. Recent clinical trials have shown promising results with SGLT2 inhibitors, incretin-related therapies, and mineralocorticoid receptor antagonists in improving renal outcomes.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Biochemistry & Molecular Biology

The Complement Pathway: New Insights into Immunometabolic Signaling in Diabetic Kidney Disease

Sih Min Tan, Matthew Snelson, Jakob A. Ostergaard, Melinda T. Coughlan

Summary: The pathogenesis of diabetic kidney disease (DKD) involves disrupted energy generation in the kidney, leading to inflammation and fibrosis. Recent studies have shown the involvement of the innate immune complement system, particularly Complement C5a and C3a, in regulating metabolic responses in the diabetic kidney.

ANTIOXIDANTS & REDOX SIGNALING (2022)

Article Endocrinology & Metabolism

Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-Sensitive Pathways

Jay C. Jha, Aozhi Dai, Jessica Garzarella, Amelia Charlton, Sofia Urner, Jakob A. Ostergaard, Jun Okabe, Chet E. Holterman, Alison Skene, David A. Power, Elif I. Ekinci, Melinda T. Coughlan, Harald H. H. W. Schmidt, Mark E. Cooper, Rhian M. Touyz, Chris R. Kennedy, Karin Jandeleit-Dahm

Summary: Excessive production of renal reactive oxygen species (ROS) plays a major role in diabetic kidney disease (DKD). This study demonstrates that NADPH oxidase 5 (NOX5) acts as a predominant pro-oxidant enzyme in DKD, independent of the previously characterized NOX4 pathway. The overexpression of NOX5 in DKD exacerbates kidney damage through enhanced ROS formation and modulation of key molecules involved in inflammation, fibrosis, and redox balance. Furthermore, the only available NOX inhibitor, GKT137831, is found to be ineffective in the presence of NOX5 expression in diabetes. These findings highlight the superior targeting potential of NOX5 as compared to other NOX isoforms like NOX4 in human DKD.

DIABETES (2022)

Editorial Material Cell Biology

Microbial influencers: treating diabetes through the gut

Matthew Snelson, Elena Rampanelli, Max Nieuwdorp, Nordin M. J. Hanssen, Melinda T. Coughlan

Summary: A recent study by Bell et al. demonstrates that dietary supplementation of modified resistant starch fibre can alter immunotolerance in individuals with type 1 diabetes.

IMMUNOLOGY AND CELL BIOLOGY (2022)

Article Nutrition & Dietetics

Reduced Growth, Altered Gut Microbiome and Metabolite Profile, and Increased Chronic Kidney Disease Risk in Young Pigs Consuming a Diet Containing Highly Resistant Protein

Margaret Murray, Melinda T. Coughlan, Anne Gibbon, Vinod Kumar, Francine Z. Marques, Sophie Selby-Pham, Matthew Snelson, Kirill Tsyganov, Gary Williamson, Trent M. Woodruff, Tong Wu, Louise E. Bennett

Summary: High-heat processed foods containing resistant proteins can lead to microbial fermentation and produce metabolites that may increase the risk of chronic diseases. This study used pigs as a model and found that a resistant protein diet altered the microbiome composition and resulted in higher levels of inflammation and the potential risk of chronic kidney disease.

FRONTIERS IN NUTRITION (2022)

Review Endocrinology & Metabolism

Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease

Vuthi Khanijou, Neda Zafari, Melinda T. Coughlan, Richard J. MacIsaac, Elif I. Ekinci

Summary: Diabetic kidney disease is a growing concern, and there is a need to identify biomarkers that can accurately predict the risk of declining kidney function. Multiple serum and urine biomarkers of inflammation and kidney injury have shown significant association with the development and progression of diabetic kidney disease. Tumor necrosis factor receptor-1 and -2 appear to be promising markers for diabetic kidney disease, while kidney injury molecule-1, beta-2-microglobulin, and neutrophil gelatinase-associated lipocalin are potential candidates for markers of kidney injury.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2022)

Review Nutrition & Dietetics

Resistant Starch as a Dietary Intervention to Limit the Progression of Diabetic Kidney Disease

Anna M. Drake, Melinda T. Coughlan, Claus T. Christophersen, Matthew Snelson

Summary: Diabetes is the leading cause of kidney disease, and resistant starch (RS) as a dietary therapy may help limit the progression of diabetic kidney disease (DKD).

NUTRIENTS (2022)

Article Multidisciplinary Sciences

Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors

Melinda T. Coughlan, Mark Ziemann, Adrienne Laskowski, Trent M. Woodruff, Sih Min Tan

Summary: Despite advances in understanding the progression of diabetic complications, diabetic kidney disease continues to be a significant health burden. In a preclinical study using diabetic mice, we found that a histone deacetylase inhibitor attenuated albuminuria and glomerulosclerosis. This inhibitor also reduced diabetes-induced upregulation of complement C5a receptors and markers of cellular senescence. Furthermore, mice lacking the C5a receptor 1 gene or treated with a C5aR1 inhibitor showed attenuated cellular senescence. These findings suggest that complement C5a mediates cellular senescence in diabetic kidney disease and complement inhibitors may serve as a novel therapeutic option.

SCIENTIFIC REPORTS (2022)

Article Cell Biology

The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes

Merlin C. Thomas, Melinda T. Coughlan, Mark E. Cooper

Summary: Recent clinical trials have shown that GLP-1RAs can have positive effects on heart and kidney outcomes in people with type 2 diabetes. This is due in part to improved glucose control and significant weight loss, but GLP-1RAs may also provide additional benefits by improving postprandial dysmetabolism.

CELL METABOLISM (2023)

Review Biochemistry & Molecular Biology

Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease

Inez A. A. Trambas, Melinda T. T. Coughlan, Sih Min Tan

Summary: Diabetic kidney disease (DKD) affects a significant percentage of patients with diabetes and is the leading cause of end-stage renal disease (ESRD). The activation of the complement cascade, a component of the innate immune system, has been implicated in the development of diabetes and its complications. Inhibition of the complement system, particularly at the level of the C5a-receptor signaling axis, shows promise in reducing inflammation and fibrosis in DKD. This review discusses the role of the C5a/C5a-receptor axis in the pathogenesis of diabetes and kidney injuries, as well as the current status and mechanisms of action of complement therapeutics in development.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

暂无数据